Small intestinal neuroendocrine cell pathobiology: 'Carcinoid' tumors

Current Opinion in Oncology

Volumn 23, Issue 1, 2011, Pages 45-52

  Kidd, Mark ^a   ModIin, Irvin M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoid; Enterochromaffin cell; Genetics; KRJ I; Microenvironment; Neuroendocrine tumor; Small intestine

Indexed keywords

ANGIOPOIETIN 2; ANGIOTENSIN I; GEFITINIB; HATH1 PROTEIN; HISTONE H1; HLA DQ2 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 2; LYMPHATIC VESSEL HYALURONAN RECEPTOR 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; OCTREOTIDE; PASIREOTIDE; PRC 08066; PROTEIN; SEROTONIN; SEROTONIN ANTAGONIST; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR PAX8; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER INHIBITION; CARCINOID; CELIAC DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG DOSE REDUCTION; ENTEROCHROMAFFIN CELL; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SMALL INTESTINE NEUROENDOCRINE TUMOR; SMALL INTESTINE TUMOR; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

CARCINOID TUMOR; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; NEUROENDOCRINE TUMORS;

EID: 79851515133     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328340d006     Document Type: Article

References (71)

1. Modlin IM, Oberg K, Chung DC, et al. The current status of gastroenteropancreatic neuroendocrine tumors. Lancet Oncology 2008; 9:61-72.
2. Evers BM, Townsend CM Jr, Upp JR, et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 1991;101:303-311.
3. Jeng YJ, Townsend CM Jr, Nagasawa S, et al. Regulation of pancreastatin release from a human pancreatic carcinoid cell line in vitro. Endocrinology 1991; 128:220-225.
4. Siddique Z-L, Drozdov I, Floch J, et al. KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model. Neuroendocrinology 2009; 89:458-470.
5. Modlin IM, Kidd M, Eick G, Champaneria M. The functional characterization of normal and neoplastic EC cells. J Clin Endocrinol Metab 2006; 91:2340-2348. (Pubitemid 43855026)
6. Kidd M, Modlin I, Gustafsson B, et al. The luminal regulation of normal and neoplastic ECcell serotonin release is mediated bybile salts, amines, tastants and olfactants. Am J Physiol 2008; 295:G260-G272.
7. Kidd M, Drozdov I, Joseph R, et al. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008; 113:690-700.
8. Kidd M, Eick G, Shapiro MD, et al. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer 2005; 103:229-236. (Pubitemid 40129280)
9. Kidd M, Modlin IM, Pfragner R, et al. Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1. Cancer 2007; 109:2420-2431. (Pubitemid 46906460)
10. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007; 19 (Suppl 2):25-31. (Pubitemid 47037963)
11. Seuwen K, Magnaldo I, Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature 1988; 335:254-256.
12. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis byserotonin. Proc Natl Acad Sci U S A 1986; 83:674-678. (Pubitemid 16035536)
13. Pakala R, Pakala R, Radcliffe JD, Benedict CR. Serotonin-induced endothelial cell proliferation is blocked by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 1999; 60:115-123. (Pubitemid 29201807)
14. Drozdov I, Kidd M, Gustafsson BI, et al. Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer 2009; 115:4934-4945.
15. Svejda B, Kidd M, Giovinazzo F, et al. The 5-HT2B receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer 2010; 116:2902-2912.
16. Chaudhry A, Oberg K, Gobl A, et al. Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res 1994; 14:2085-2091.
17. Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993; 32:107-114. (Pubitemid 23188522)
18. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26:1316-1323.
19. Detjen KM, Rieke S, Deters A, et al. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 2010; 16:420-429.
20. Tomita T. Lymphatic vessel endothelial hyaluronan receptor 1 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors. Pancreas 2007; 35:e18-e22. (Pubitemid 350307392)
21. Tomita T. LYVE-1 immunocytochemical staining for gastrointestinal carcinoids. Pathology 2009; 41:248-253.
22. Warneboldt J, Haller F, Horstmann O, et al. Histone H1× is highly expressed in human neuroendocrine cells and tumours. BMC Cancer 2008; 8:388.
23. Khatami M. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases. Cell Biochem Biophys 2009; 55:55-79.
24. Hartupee JC, Zhang H, Bonaldo MF, et al. Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: Reg IV. Biochim Biophys Acta 2001; 1518:287-293. (Pubitemid 32324196)
25. Shroyer NF, Helmrath MA, Wang VY, et al. Intestine-specific ablation of mouse atonal homolog 1 (Math1) reveals a role in cellular homeostasis. Gastroenterology 2007; 132:2478-2488. (Pubitemid 46890862)
26. Heiskala K, Arola J, Heiskala M, Andersson LC. Expression of Reg IV and Hath1 in neuroendocrine neoplasms. Histol Histopathol 2010; 25:63-72.
27. Hiripi E, Bermejo JL, Sundquist J, Hemminki K. Familial gastrointestinal carcinoid tumours and associated cancers. Ann Oncol 2009; 20:950-954.
28. Hemminki K, Li X. Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 2001; 94:444-448. (Pubitemid 32906079)
29. Hassan MM, Phan A, Li D, et al. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17:959-965. (Pubitemid 351536429)
30. Jarhult J, Landerholm K, Falkmer S, et al. First report on metastasizing small bowel carcinoids in first-degree relatives in three generations. Neuroendocrinology 2010; 91:318-323.
31. Zikusoka M, Kidd M, Eick G, et al. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005; 104:2292-2309. (Pubitemid 41691550)
32. Calender A. Molecular genetics of neuroendocrine tumors. Digestion 2000; 62 (Suppl 1):3-18. (Pubitemid 30665934)
33. Vikman S, Giandomenico V, Sommaggio R, et al. CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients. Cancer Immunol Immunother 2008; 57:399-409. (Pubitemid 350295384)
34. Vikman S, Sommaggio R, De La Torre M, et al. Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue. Acta Oncol 2009; 48:391-400.
35. Berkovic MC, Jokic M, et al. IL-2-330T/G SNP and serum values-potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NETs). J Mol Med 2010; 88:423-429.
36. Kidd M, Gustafsson Bl, Drozdov I, Modlin IM. ILIbeta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease. Neurogastroenterol Motil 2009; 21:439-450.
37. Bishop AE, Pietroletti R, Taat CW, et al. Increased populations of endocrine cells in Crohn's ileitis. Virchows Arch A Pathol Anat Histopathol 1987; 410:391-396. (Pubitemid 17022443)
38. West NE, Wise PE, Herline AJ, et al. Carcinoid tumors are 15 times more common in patients with Crohn's disease. Inflamm Bowel Dis 2007; 13:1129-1134. (Pubitemid 47402597)
39. Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol 2007; 133:859-866. (Pubitemid 350218912)
40. Zhou B, Rao L, Li Y, et al. A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett 2009; 275:72-76.
41. Burnik FS, Yalcin S. NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy 2009; 55:381-385.
42. Wang Q, Fang WH, Krupinski J, et al. Pax genes in embryogenesis and oncogenesis. J Cell Mol Med 2008; 12:2281-2294.
43. Sosa-Pineda B. The gene Pax4 is an essential regulator of pancreatic beta-cell development. Mol Cells 2004; 18:289-294. (Pubitemid 40298022)
44. Long KB, Srivastava A, Hirsch MS, Hornick JL. PAX8 expression in well differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol 2010; 34:723-729.
45. Rindi G, Kloppel G. Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 2004; 80 (Suppl 1):12-15. (Pubitemid 39382361)
46. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451:757-762. (Pubitemid 47497934)
47. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014:13-27. (Pubitemid 38594787)
48. Kloppel G, Rindi G, Perren A, et al. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch 2010; 456:595-597.
49. Klimstra D, Modlin I, Adsay N, et al. Pathologic reporting of neuroendocrine tumors: application ofthe Delphic consensus process to the developmentofa minimum pathologic data set. Am J Pathol 2010; 34:300-313.
50. Washington MK, Tang LH, Berlin J, et al. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the small intestine and ampulla. Arch Pathol Lab Med 2010; 134:181-186.
51. Drozdov I, Kidd M, Nadler B, et al. Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer 2009; 115:1638-1650.
52. Ahlman H, Nilsson O, McNicol AM, et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology 2008; 87:40-46. (Pubitemid 350308293)
53. Marko NF, Prayson RA, Barnett GH, Weil RJ. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study. Genomics 2010; 95:16-24.
54. Peters CJ, Rees JR, Hardwick RH, et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 2010. [Epub ahead of print]
55. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-536. (Pubitemid 34130608)
56. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-2826. (Pubitemid 40051905)
57. Arnold R, Muller H, Schade-Brittinger C, et al. Placebo-controlled, doubleblind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. ASCO 2009, Gastrointestinal Cancers Symposium, Abstract 121; 2009.
58. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-4663.
59. Chua YJ, Michael M, Zalcberg JR, et al. Antitumor effect of somatostatin analogs in neuroendocrine tumors. J Clin Oncol 2010; 28:e41 -e42; author reply e43-e44.
60. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31:169-188.
61. Schmid HA. Preclinical evidences suggest new treatment options for endocrine disorders: pasireotide (SOM230) and everolimus (RAD001). Ann Endocrinol (Paris) 2008; 69:162-163.
62. Hobday T, Rubin J, Holen K, et al. MC044 h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol 2007; 25:4504.
63. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26:3403-3410.
64. Hobday T, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol 2006; 24:189s.
65. Gilbert JA, Lloyd RV, Ames MM. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. N Engl J Med 2005; 353:209-210. (Pubitemid 41058357)
66. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006; 13:535-540. (Pubitemid 43886675)
67. Modlin I, Gustafsson B, Pavel M, et al. A nomogram to assess small intestinal neuroendocrine tumor ('carcinoid') survival. Neuroendocrinology 2010. [Epub ahead of print]
68. Challacombe DN, Robertson K. Enterochromaffin cells in the duodenal mucosa of children with coeliac disease. Gut 1977; 18:373-376. (Pubitemid 8128040)
69. Sjolund K, Alumets J, Berg NO, et al. Enteropathy of coeliac disease in adults: increased number of enterochromaffin cells the duodenal mucosa. Gut 1982; 23:42-48. (Pubitemid 12170174)
70. HallertC, Norrby K. Malignantcarcinoid tumour complicating coeliac disease. Acta Med Scand 1983; 213:313-316. (Pubitemid 13097300)
71. Lito P, Pantanowitz L, Marotti J, et al. Gastroenteropancreatic neuroendocrine tumors in patients with HIV infection: a trans-Atlantic series. Am J Med Sci 2009; 337:1-4.